The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
about
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stressA phase 2 study of vorinostat in acute myeloid leukemiaPCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cellsp53 acetylation is crucial for its transcription-independent proapoptotic functionsThe histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responsesTargeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implicationsGranzyme M mediates a novel form of perforin-dependent cell deathOvercoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanatePreclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinomaTrichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cellsVorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cellsRegulation of cell migration and survival by focal adhesion targeting of Lasp-1Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.Rhodanese-thioredoxin system and allyl sulfur compounds.Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancerRole of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathwayPotent and orally efficacious bisthiazole-based histone deacetylase inhibitorsBortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.Oxidative stress in NSC-741909-induced apoptosis of cancer cellsThe pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoIdentification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cellsProteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaHistone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
P2860
Q23918915-95A6ADAC-B91F-454D-9314-4159EC0FBCBAQ24643266-CAD22ECE-3F0A-40F8-BB4F-C0C81B88A6B0Q24654958-625873E8-AF05-4EA9-8959-6B5844F24CDAQ24657909-9CB8898F-4D83-45B4-9F04-7A0B39706B20Q24796904-514D658C-DB70-43A8-99C0-A08655EC2B5FQ26853394-86DCFB43-843A-4F57-9C31-33589FB7E744Q28251140-A2CC4152-8232-4A38-B3BD-6449DF9B44D8Q28383320-447DDA72-7791-4DDA-B32B-45984E25C2D2Q28395338-E11F65EC-0231-4E96-9563-ACAA146708D0Q28540870-54DCFCFE-0D73-45E1-9CE3-17D47AF6C391Q28743758-1E292052-D20C-4EF0-BD8E-52E6527ECF76Q30164085-0E96605A-ED95-4165-A8CC-46B97A90C7CBQ30873726-CEE3ED37-373A-4B67-A384-3DFA086B8D5CQ31162170-8AB81ADD-65B6-45AF-AAEB-AFB14D5EF783Q33249818-63959C52-D961-4EDC-8DF6-5C8B142D26F7Q33425333-41937401-0115-46CA-A1A7-CE352941C37FQ33427979-1C03AE9B-25BD-44BC-96C5-A63AD4311B1CQ33583208-C4F8D879-A850-413D-AA1C-0EAEC2C0D094Q33651762-D5EECE75-DBFA-4C34-A32A-3970C3E0EA80Q33697130-1922B1EB-BE94-4818-9929-BA1899BE310DQ33705588-1D107F43-6768-422A-B973-2FA9437DEBE5Q33741142-4E2168B9-A13A-49B7-8A58-7DB82CEFBE07Q33744417-CF405A64-EAAD-4BC2-9489-15299A40EC42Q33768549-F3D4E890-19B6-4CAD-95A2-79B22E092C6FQ33798624-14AEC69F-D8A4-4555-8B3F-5FDF70550CF0Q33800456-836C56F6-35F3-4EC4-854D-EF27A40C433AQ33829390-EE006361-FC36-40FD-B160-42E82128DFD3Q33863049-3EEE7A32-FAC1-4629-A48F-C3EEE58B3AA2Q33863911-129AFE04-C2CB-4C64-97C0-F3389BEC02ACQ33896749-9E211FA3-5D31-461B-A6CB-3150869B1C75Q33926864-A28E7C4A-73BD-4554-89E8-90400E6BC772Q33952785-DA93F411-AE1A-4AC5-ADF0-C17B280B05C7Q33962243-BC93CE96-9FDF-4A46-A1CC-0B5176AB3794Q33983255-07B7CC60-7063-450C-A4BD-A262F94DDD0FQ34014818-B99329B4-31F4-4669-A6CE-89A1C63E4A58Q34093052-11A1C999-6EB9-465F-94D7-57D96206FD0AQ34114810-779B666B-1A98-4FE8-A566-772CE15B32B4Q34145992-731EC88C-D7F5-41F1-8239-9D4A29D1A321Q34224278-4EBE9F04-5692-4689-9753-A05E9545FF4FQ34240470-3C2EEF81-D6CD-442D-9633-0959BBFB336F
P2860
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The histone deacetylase inhibi ...... ion of reactive oxygen species
@ast
The histone deacetylase inhibi ...... ion of reactive oxygen species
@en
The histone deacetylase inhibi ...... ion of reactive oxygen species
@nl
type
label
The histone deacetylase inhibi ...... ion of reactive oxygen species
@ast
The histone deacetylase inhibi ...... ion of reactive oxygen species
@en
The histone deacetylase inhibi ...... ion of reactive oxygen species
@nl
prefLabel
The histone deacetylase inhibi ...... ion of reactive oxygen species
@ast
The histone deacetylase inhibi ...... ion of reactive oxygen species
@en
The histone deacetylase inhibi ...... ion of reactive oxygen species
@nl
P2093
P2860
P50
P3181
P356
P1476
The histone deacetylase inhibi ...... ion of reactive oxygen species
@en
P2093
A A Ruefli
D Bernhard
K M Tainton
V R Sutton
P2860
P304
10833-10838
P3181
P356
10.1073/PNAS.191208598
P407
P577
2001-09-04T00:00:00Z